Neuraxpharm Enters Japanese Market
Follows Buccolam Deal With Takeda Last Year
Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.
You may also be interested in...
Neuraxpharm Recruits Another Viatris Executive To Lead European Expansion
For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.
Neuraxpharm Expands Into The Nordics With New Leader From Viatris
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.
Neuraxpharm CEO Confirms Expansion Into New Markets, Including US
In an exclusive interview with Generics Bulletin, Neuraxpharm CEO Jörg-Thomas Dierks reveals that the company plans to expand out of Europe into other markets by acquiring companies in regions such as the US.